AR and pulmonary fibrosis: Moreover, a significant decrease in IL-13, responsible for mucus hypersecretion, goblet cell metaplasia, non-specific airway hyperreactivity, fibrosis, IgE production, and asthma (Doran et al. 2017), pave the ability of AR-B to be used in IL-13 restraining approach to overcome lung fibrosis (Chung et al. 2016).